Insight

Meng-Ju Wu: IDH1 inhibition activates tumor immunity by inducing dsDNA sensing

Photo from Meng-Ju Wu/LinkedIn

Jul 15, 2024, 11:28

Meng-Ju Wu: IDH1 inhibition activates tumor immunity by inducing dsDNA sensing

Meng-Ju Wu, Instructor at Harvard Medical School and Massachusetts General Hospital, shared on X about a recent paper titled “Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity” published in Science.

Authors: Meng-Ju Wu, Hiroshi Kondo, Ashwin V. Kammula, Lei Shi, Yi Xiao, Sofiene Dhiab, Qin Xu, Chloe J. Slater, Omar I. Avila, Joshua Merritt, Hiroyuki Kato, Prabhat Kattel, Jonathan Sussman, Ilaria Gritti, Jason Eccleston, Yi Sun, Hyo Min Cho, Kira Olander, Takeshi Katsuda, Diana D. Shi, Milan R. Savani, Bailey C. Smith, James M. Cleary, Raul Mostoslavsky, Vindhya Vijay, Yosuke Kitagawa, Hiroaki Wakimoto, Russel W. Jenkins, Kathleen B. Yates, Jihye Paik, Ania Tassinari, Duygu Hatice Saatcioglu, Adriana E. Tron, Wilhelm Haas, Daniel Cahill, Samuel K. Mcbrayer, Robert T. Manguso and Nabeel Bardeesy.

Meng-Ju Wu

“New in Science Magazine! Our study reveals how mutant IDH1 inhibition activates tumor immunity by inducing dsDNA sensing.

Many cancers are driven by mutations in isocitrate dehydrogenase 1 (IDH1). Recently, drugs targeting mutant IDH1 (mIDH1) have effectively slowed tumor growth, though their precise mechanism was unclear.

Key Insight: Mutant IDH1 inhibits demethylases, blocking gene expression. We discovered that mIDH1 inhibitors lead to widespread demethylation, reactivating viral gene left in the genome from ancient infections and of CGAS, the protein that detects them.

This reactivation triggers a viral mimicry response, activating the immune system to kill tumor cells. In preclinical models, mIDH1 inhibition led to rapid CD8+ T cell recruitment and robust anti-tumor immunity.

Meng-Ju Wu

Our findings suggest enhancing viral mimicry and immune-stimulating strategies could improve mIDH1 inhibitor effectiveness, paving the way for new combination therapies.

Thanks to our amazing team! Kudos to Hiroshi Kondo and Ashwin Kammula for working with me on this study. I want to thank my mentor, Nabeel Bardeesy and Rob Manguso for supporting this project! And many thanks for all the collaborators and colleagues.

Besides the cholangiocarcinoma study, I also want to thank our glioma research collaborators: Sam McBrayer, Yi Xiao, Daniel Cahill, Yosuke Kitagawa, and Hiroaki Wakimoto. This work could not have been done without you!

I also want to thank Kate Fitzgerald and Pitarresi for writing this excellent perspective on our study.

Finally, I’ll be starting my own lab at UMass Chan Medical School this October. Interested in our research? Check out my website. If you are interested in research associate or postdoc positions, please feel free to contact me by DM or email.”

Source: Meng-Ju Wu/X .

Adriana E. Tron Ania Tassinari Ashwin V. Kammula Bailey C. Smith Broad Institute cancer Chloe J. Slater cholangiocarcinoma Daniel Cahill demethylases Diana D. Shi dsDNA Duygu Hatice Saatcioglu Harvard Medical School and Massachusetts General Hospital Hiroaki Wakimoto Hiroshi Kondo Hiroyuki Kato Hyo Min Cho IDH1 inhibition Ilaria Gritti James M. Cleary Jason Eccleston Jihye Paik Jonathan Sussman Joshua Merritt Kate Fitzgerald Kathleen B. Yates Kira Olander Lei Shi Meng-Ju Wu Milan R. Savani Nabeel Bardeesy Omar I. Avila OncoDaily Oncology Pitarresi Prabhat Kattel Qin Xu Raul Mostoslavsky Rob Manguso Robert T. Manguso Russel W. Jenkins Samuel K. Mcbrayer Science Science Magazine Sofiene Dhiab Takeshi Katsuda tumor UMass Chan Medical School Vindhya Vijay Wilhelm Haas Yi Sun Yi Xiao Yosuke Kitagawa

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage